227 results on '"Bäck, Tom"'
Search Results
2. Optimised solid-phase extraction of 211At: Activity balance of 211At, 210At and 210Po after wet chemistry target dissolution
3. 211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.
4. A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In Vitro
5. Beta and Alpha Particle Autoradiography
6. Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211
7. Data from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
8. Supplementary Data, Supplementary Figures 1 and 2, Supplementary Tables 1-6 from Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
9. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
10. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
11. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
12. Astatine-211 based radionuclide therapy: Current clinical trial landscape
13. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
14. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
15. Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy
16. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
17. Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy.
18. Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy
19. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
20. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
21. Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy
22. Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy.
23. Estimating the risk for secondary cancer following targeted alpha therapy with astatine-211 intraperitoneal radioimmunotherapy.
24. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
25. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
26. Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223
27. Radium-223–Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow
28. Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer
29. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′) 2: therapeutic efficacy and myelotoxicity
30. Astatine-211: The Chemistry Infrastructure
31. Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations
32. Estimation of Long-term Risks for Cancer Induction following Adjuvant Targeted Alpha Therapy with Curative Intent
33. Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with223Ra: The Role of Bystander Effects and Their Potential for Therapy
34. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
35. Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
36. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields
37. Dose‐Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with Radium‐223: The Role of Bystander Effects and their Potential for Therapy.
38. Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations.
39. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
40. Abstract 834: Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with211At-mAb
41. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
42. Alpha imaging confirmed efficient targeting of CD45-positive cells after astatine-211 (211At)-radioimmunotherapy for hematopoietic cell transplantation
43. BIOTINYLATED AND CHELATED POLY-L-LYSINE AS EFFECTOR FOR PRETARGETING IN CANCER THERAPY AND IMAGING
44. Intraperitoneal a-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
45. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
46. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
47. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors
48. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.
49. Alpha-radioimmunotherapy with At-211: Evaluations and imaging on normal tissues and tumors
50. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.